NetworkNewsBreaks

WednesdayAug 16, 2023 2:35 pm

NetworkNewsBreaks – Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) (FSE: HF2) Mobilizes Drill Rigs, Advances Exploration Efforts at Ruby Graphite Project

Reflex (CSE: RFLX) (OTCQB: RFLXF) (FSE: HF2) today announced the mobilization of drill equipment for its Summer 2023 initial drill program at the Ruby Graphite project in Montana. Drill pad construction is underway for the program, which is planned to consist of 3,500 meters of core drilling at the project, located in Beaverhead County, Montana, U.S.A. “The mobilization of drill rigs marks an important milestone for Reflex as we advance our exploration efforts at the Ruby Graphite project,” said Paul Gorman, CEO of Reflex Advanced Materials. “We are confident that this drill program will not only confirm the presence of…

Continue Reading

WednesdayAug 16, 2023 2:27 pm

NetworkNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Enters into Agreements for $5M Registered Direct Offering

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, has entered into definitive agreements. The offering is expected to close on or about Aug. 18, 2023, and will be subject to customary closing conditions. The company anticipates gross proceeds from the registered direct offering to total approximately $5 million; RVL Pharmaceuticals plans to use the funds for general corporate purposes. The registered direct offering agreements are for the purchase and sale of 11,870,846 of RVLP ordinary shares (or ordinary…

Continue Reading

WednesdayAug 16, 2023 1:56 pm

NetworkNewsBreaks – Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) Announces Commencement of Modular Horizontal Infill Well Program

Prospera (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) today announced the spudding of the first horizontal well of the 10-well modular multi-pad infill drill program in the latter part of this week, subject to any weather-related or uncontrollable delays. According to the update, close to a hundred services have been coordinated along with lease preparation, permits and licenses. This drill program stems from a comprehensive geological, seismic and reservoir management delineation designed to cost-effectively optimize recovery with optimum wells while aligning with planned enhanced and improved recovery techniques. As previously announced, this 10-well program can add an approximately 750 bpd at…

Continue Reading

WednesdayAug 16, 2023 12:38 pm

NetworkNewsBreaks – Jupiter Wellness Inc.’s (NASDAQ: JUPW) Subsidiary Announces Pricing of Its IPO

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced that SRM Entertainment Inc. (NASDAQ: SRM), currently a subsidiary of the company, announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a price to the public of $5.00 per share. Gross proceeds from the offering are expected to be $6.25 million. The shares of SRM began began trading under the symbol SRM on the Nasdaq Capital Market on Aug. 15, 2023. Subject to the satisfaction of customary conditions, the offering is expected to close on Aug. 16, 2023. In…

Continue Reading

WednesdayAug 16, 2023 12:04 pm

NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is featured in a recent Aegis Capital Corp. research report. Aegis titled the report “Good Things Coming” and gave BVXV a Buy rating. The research report noted that BiondVax has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies, called NanoAbs, targeting Interleukin-17 (“IL-17”), specifically for the treatment of psoriasis and psoriatic arthritis. The agreement is with the Max Planck Society and the University Medical Center Gottingen (“UMG”) and is part of…

Continue Reading

WednesdayAug 16, 2023 11:07 am

NetworkNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Bright Future in Advancing Potentially Curative Therapies

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), is focused on advancing treatments for some of the world’s deadliest diseases. In late 2022, the company announced the award of a U.S. patent for its oncology platform, as well as promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. Scientists at the Fred Hutchinson Cancer Center were also, at that time, conducting studies of the company’s HIV platform with expected positive results. “We continue to prioritize the efficient research, development and commercialization of our promising oncology and HIV pipelines,” said the company’s CEO Dr. Mark Dybul. “Enochian’s…

Continue Reading

WednesdayAug 16, 2023 10:37 am

NetworkNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Unveils Ultra-High-Performance FIVE RS Crossover

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, announced its newest mode: the ultra-high-performance Mullen FIVE RS EV Crossover. According to the announcement, the newest addition to MULN’s offerings features a top speed of more than 200 mph and can accelerate from 0–60 mph in under two seconds. The FIVE RS is equipped with 800-volt architecture, all-wheel drive, a two-speed gearbox and more than 1,100 horsepower. MULN is planning to showcase the model at this season’s kickoff of its Strikingly Different EV tour, which begins on Aug. 20, 2023, in Austin, Texas. The company noted that because of…

Continue Reading

TuesdayAug 15, 2023 3:48 pm

NetworkNewsBreaks – Axis Technologies Group Inc. (AXTG) CEO Eyes Opportunity in the Digitization Space in Shareholder Update

Axis Technologies (OTC: AXTG) today issued a letter to shareholders from its Chief Executive Officer Dr. William Tien. The communication served as an opportunity to provide a comprehensive overview of the company’s developments and to highlight remarkable strides it has made. “We have always positioned ourselves to be in the forefront of the continuously growing and evolving marketplace in digitization space,” Dr. Tien writes in the update. “We firmly believe that we will be successful as we continuously strive to identify those areas and opportunities to enhance the blockchain ecosystem and to further develop those tools and systems necessary for…

Continue Reading

TuesdayAug 15, 2023 2:03 pm

NetworkNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Provides Q2 Update Video, Announces New ASR Deployment, Adds Roadshow Date to Calendar

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has released its Second Quarter 2023 Town Hall Update video. The company recorded its Aug. 14, 2023, town hall event; the video is available on the company website for those who were unable to attend the gathering in person. In addition, the company announced the latest deployment of its ASR security solutions. According to the announcement, a K5 ASR has been deployed in North Carolina by KSCP reseller Weatherspoon Enterprises, Inc., a North Carolina-based integrated security services and solutions provider. Weatherspoon offers the…

Continue Reading

TuesdayAug 15, 2023 1:21 pm

NetworkNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Committed to Rapid Advancement of Its Proprietary Oncology Platform

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), in late 2022, was awarded a U.S. patent for its proprietary cancer treatment platform that could potentially be used to induce life-long remission from some of the world’s deadliest solid tumors. “We are incredibly excited to have been awarded this patent for Enochian’s allogeneic cell and gene therapy cancer treatment platform, especially following promising early study results,” said the company’s CEO Dr. Mark Dybul. “This technology could be transformative for oncology and for treating some of the world’s deadliest cancers, including pancreatic cancer, which has a five-year survival rate of just 5% to…

Continue Reading